Global Follicular Lymphoma Treatment Market Size 2024, Forecast To 2033
6 Mar, 2024
The follicular lymphoma treatment market has witnessed robust growth, escalating from $2.83 billion in 2023 to $3.09 billion in 2024, indicating a substantial compound annual growth rate (CAGR) of 9.0% during the historic period. This growth is attributed to factors such as the increased incidence of follicular lymphoma, advancements in cancer diagnostics, the expanding aging population, ongoing clinical research, drug development, and collaborative efforts in oncology research. Looking ahead to 2028, the market is anticipated to experience strong growth, projecting a size of $4.2 billion with a CAGR of 8.0%. Key drivers for this anticipated growth include personalized medicine approaches, advancements in immunotherapy, expanded access to innovative therapies, a heightened focus on the quality of life for patients, and global collaboration initiatives in the field of oncology. Major trends in the forecast period encompass clinical trials and research initiatives, exploration of epigenetic modifiers, enhancements in radioimmunotherapy, the application of artificial intelligence (AI), and global collaboration for improved access to therapies.
Global Follicular Lymphoma Treatment Market Key Driver
The rising prevalence of follicular lymphoma is expected to propel the growth of the follicular lymphoma treatment market moving forward. The prevalence of follicular lymphoma refers to the total number or proportion of individuals within a specific population diagnosed with follicular lymphoma at a given time or over a particular period. This shift has resulted from the rise in the aging population, genetic predisposition, improved diagnostic techniques, and increased awareness and screening. Follicular lymphoma treatment helps reduce the prevalence of follicular lymphoma by addressing the disease at various stages and aids in disease treatment and progression. The rise in the incidence of follicular lymphoma is boosting the growth of the follicular lymphoma treatment market. For instance, in January 2023, according to the American Cancer Society, a US-based Voluntary organization, non-Hodgkin lymphoma, a type of indolent follicular lymphoma, is the most frequent cancer in the US, accounting for around 4% of all cancers. The American Cancer Society projects that NHL will be diagnosed in approximately 80,550 persons (44,880 men and 35,670 women). This includes both adults and children. Therefore, the rising prevalence of follicular lymphoma is driving the growth of the follicular lymphoma treatment market. The follicular lymphoma treatment market is anticipated to expand significantly by 2028, reflecting the increasing need for advanced treatment options and therapies to address the growing prevalence of follicular lymphoma globally.
Get A Free Sample Of The Global Follicular Lymphoma Treatment Market ReportGlobal Follicular Lymphoma Treatment Market Segments
The follicular lymphoma treatment market covered in this report is segmented –
1) By Treatment: Monoclonal Antibodies, Targeted Therapy, Chemotherapy, Radiation Therapy, Stem Cell Transplant, Alkylating Agents, Nucleoside Analogues, Anthracycline Derivatives, Other Treatments
2) By Product Type: Tablets, Capsules, Injectables, Other Product Types
3) By Route of Administration: Oral, Parenteral, Other Route of Administration
4) By End Use: Hospitals, Oncology Centers, Ambulatory Care Centers, Academic Research Institutes, Other End Users
By Geography:The regions covered in the follicular lymphoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
North America was the largest region in the follicular lymphoma treatment market in 2023. The regions covered in the follicular lymphoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Follicular Lymphoma Treatment Industry Players
AbbVie Inc.,Celgene Corporation,Bayer AG,Bristol Myers Squibb Company,F. Hoffmann-La Roche Ltd.,Johnson and Johnson Services Inc.,GlaxoSmithKline plc,Novartis AG,Merck & Co. Inc.,EpiZyme Inc.,Boehringer Ingelheim GmbH,CTI BioPharma Corp.,Spectrum Pharmaceuticals Inc.,Seattle Genetics Inc.,Applied Molecular Genetics Inc.,Daiichi Sankyo Company Ltd.,Pfizer Inc.,Incyte Corporation,MorphoSys AG,Regeneron Pharmaceuticals Inc.,Eli Lilly and Company,Seagen Inc.,Takeda Pharmaceutical Company,Abbott Laboratories, Nordic Nanovector ASA,ADC Therapeutics SA,MEI Pharma Inc.,BeiGene Inc.,TG Therapeutics Inc.,Amgen Inc.,Dr. Reddy's Laboratories Ltd.
Get The Full Global Follicular Lymphoma Treatment Market Report
Follicular Lymphoma Treatment Market Overview
Follicular lymphoma treatment refers to the medical interventions and therapies aimed at managing and combating the progression of follicular lymphoma, a type of non-Hodgkin lymphoma characterized by abnormal cell growth in the lymphatic system. The medication is often administered into a vein (intravenously). Radiation therapy can be used to treat early-stage follicular lymphoma.
Follicular Lymphoma Treatment Global Market Report 2023 provides data on the global follicular lymphoma treatment market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The follicular lymphoma treatment market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.